Detection of OSR2, VAV3, and PPFIA3 Methylation in the Serum of Patients with Gastric Cancer

Li, Wen-han; Zhou, Zhangjian; Huang, Tianhe; Guo, Kun; Chen, Wei; Wáng, Ying; Zhang, Hao; Song, Yi; Chang, Dongdong

doi:10.1155/2016/5780538

Cited by 19 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several molecular detection methods, such as methylation-specific PCR (MSP) or quantitative MSP (qMSP), were applied in enrolled studies. One study [ 15 ] used bisulfite genomic sequence and another [ 23 ] used Taqman PCR to measure the status of specific circulating DNA in GC patients. The blood volume used for DNA detection varied between 400 ul–5 ml with a median volume of 1.5ml.…”

Section: Resultsmentioning

confidence: 99%

Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis

Gao

Zhang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

BackgroundCirculating tumor DNA (ctDNA) has offered a minimally invasive approach for detection and measurement of gastric cancer (GC). However, its diagnostic and prognostic value in gastric cancer still remains unclear.ResultsA total of 16 studies comprising 1193 GC patients met our inclusion criteria. The pooled sensitivity and specificity were 0.62 (95% confidence intervals (CI) 0.59−0.65) and 0.95 (95% CI 0.93–0.96), respectively. The AUSROC (area under SROC) curve was 0.94 (95% CI 0.89–0.98). The results showed that the presence of certain ctDNA markers was associated with larger tumor size (OR: 0.26, 95% CI 0.11–0.61, p = 0.002), TNM stage (I + II/III + IV, OR: 0.11, 95% CI 0.07−0.17, p = 0.000), as well as H. pylori infection. (H.p negative/H.p positive, OR: 0.57, 95% CI 0.36–0.91, p = 0.018). Moreover, there was also a significant association between the presence of ctDNA and worse overall survival (HR 1.77, 95% CI 1.38−2.28, p < 0.001), as well as disease-free survival (HR 4.36, 95% CI 3.08−6.16, p < 0.001).Materials and MethodsPubmed, Embase, Cochrane Library and Web of Science databases were searched for relating literature published up until November 30, 2016. Diagnostic accuracy variables were pooled by the Meta-Disc software. Engauge Digitizer and Stata software were applied for prognostic data extraction and analysis.ConclusionsOur meta-analysis indicates the detection of certain ctDNA targets is significantly associated with poor prognosis of GC patients, with high specificity and relatively moderate sensitivity.

show abstract

Section: Resultsmentioning

confidence: 99%

Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis

Gao

Zhang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…A study on whole-exome sequencing identified that PTPN12 variant is associated with CRC susceptibility [46]. In addition, the methylation of PTPRF-interacting protein alpha 3(PPFIA3) in serum has shown a potential for the detection of gastric cancer [47].…”

Section: Discussionmentioning

confidence: 99%

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

Onwuka

Liu

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Differential DNA methylation panel derived from peripheral blood could serve as biomarkers of CRC susceptibility. However, most of the previous studies utilized post-diagnostic blood DNA which may be markers of disease rather than susceptibility. In addition, only a few studies have evaluated the predictive potential of differential DNA methylation in CRC in a prospective cohort and on a genome-wide basis. The aim of this study was to identify a potential panel of DNA methylation biomarkers in peripheral blood that is associated with CRC risk and therefore serve as epigenetic biomarkers of disease susceptibility. Methods: DNA methylation profile of a nested case-control study with 166 CRC and 424 healthy normal subjects were obtained from the Gene Expression Omnibus (GEO) database. The differentially methylated markers were identified by moderated t-statistics. The DNA methylation panel was constructed by stepwise logistic regression and the least absolute shrinkage and selection operator in the training dataset. A methylation risk score (MRS) model was constructed and the association between MRS and CRC risk assessed. Results: We identified 48 differentially methylated CpGs sites, of which 33 were hypomethylated. Of these, sixteen-CpG based MRS that was associated with CRC risk (OR = 2.68, 95% CI: 2.13, 3.38, P < 0.0001) was constructed. This association is confirmed in the testing dataset (OR = 2.02, 95% CI: 1.48, 2.74, P < 0.0001) and persisted in both males and females, younger and older subjects, short and long time-to-diagnosis. The MRS also predicted CRC with AUC 0.82 (95% CI: 0.76, 0.88), indicating high accuracy. Conclusions: Our study has identified a novel DNA methylation panel that is associated with CRC and could, if validated be useful for the prediction of CRC risk in the future.

show abstract

“…A study on whole-exome sequencing identi ed that PTPN12 variant is associated with CRC susceptibility (46). In addition, the methylation of PTPRF-interacting protein alpha 3(PPFIA3) in serum has shown a potential for the detection of gastric cancer (47).…”

Section: Discussionmentioning

confidence: 99%

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

Onwuka

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Differential DNA methylation panel derived from peripheral blood could serve as biomarkers of CRC susceptibility. However, most of the previous studies utilized post-diagnostic blood DNA which may be markers of disease rather than susceptibility. In addition, only few studies has evaluated the predictive potential of differential DNA methylation in CRC in a prospective cohort and on a genome-wide basis. The aim of this study was to identify potential panel of DNA methylation biomarkers in peripheral blood that are associated with CRC risk and therefore serve as epigenetic biomarkers of disease susceptibility.Methods: DNA methylation profile of a nested case-control study with 166 CRC and 424 healthy normal subjects were obtained from Gene Expression Omnibus (GEO) database. The differentially methylated markers were identified by moderated t-statistics. The DNA methylation panel were constructed by stepwise logistic regression and least absolute shrinkage and selection operator in training dataset. A methylation risk score (MRS) model was constructed and the association between MRS and CRC risk assessed. Results: We identified 48 differentially methylated CpGs sites, of which 33 were hypomethylated. Of these, sixteen-CpG based MRS that was associated with CRC risk (OR = 2.68, 95% CI: 2.13, 3.38, P < 0.0001) was constructed. This association is confirmed in the testing dataset (OR = 2.02, 95% CI: 1.48, 2.74, P < 0.0001) and persisted in both males and females, younger and older subjects, short and long time-to-diagnosis. The MRS also predicted CRC with AUC 0.82 (95% CI: 0.76, 0.88), indicating high accuracy. Conclusions: Our study has identified a novel DNA methylation panel that is associated with CRC and could, if validated be useful for the prediction of CRC risk in the future.

show abstract

Detection of OSR2, VAV3, and PPFIA3 Methylation in the Serum of Patients with Gastric Cancer

Cited by 19 publications

References 32 publications

Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis

Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility

Contact Info

Product

Resources

About